Staff

PROFESSOR BRIAN LIPWORTH

BACK TO PUBLICATIONS

Letters and Correspondence

C1 LIPWORTH BJ, WOODCOCK A, ADDIS B, TURNER-WARWICK M. Late relapse of desquamative interstitial pneumonia. American Review of Respiratory Disease 1987; 136: 1253-1255.

C2 LIPWORTH BJ, DHILLON DP, CLARK RA, NEWTON RW. Problems with asthma following treatment of thrytoxicosis. British Journal of Diseases of the Chest 1988; 82: 310-314.

C3 LIPWORTH BJ, MCMURRARY JJ, CLARK RA, STRUTHERS AD. Development of persistent late onset asthma following treatment with captopril. European Respiratory Journal 1989; 2: 586-588.

C4 LIPWORTH BJ, SLATER DN, CORRIN B, KESSELER MR, HASTE AR. Allergic granulomatosis without asthma: a rate forme fruste of the Churg-Strauss syndrome. Respiratory Medicine 1989; 83: 249-250.

C5 LIPWORTH BJ, OAKLET DGD. Surgical treatment of constrictive pericarditis due to practolol. Journal of Cardiovascular Surgery 1988; 29: 408-409.

C6 LIPWORTH BJ & DHILLON DP. A case of eosinophilic pleural effusion complicating multiple myeloma. Scottish Medical Journal 1988; 33: 278.

C7 FRASER CG & LIPWORTH BJ. Analytical goals for theophylline assays. Clinical Chemistry 1988; 34: 796-797.

C8 LIPWORTH BJ, NEWNHAM DM, MCDEVITT DG. Beta-agonists in asthma. Lancet 1991; 337: 45.

C9 SMITH RP, LIPWORTH BJ. PneumoThorax resulting from bronchial brushing during fibre-optic bronchoscopy. Respiratory Medicine 1994; 88: 73.

C10 LIPWORTH BJ, GROVE A. tolerance with beta-agonists. Lancet 1993; 342: 1306.

C11 CARGILL RI, BOYTER A, LIPWORTH BJ. Reversible myocardial ischaemia following vincristine containing chemotherapy. Respiratory Medicine 1994; 88: 709-710.

C12 LIPWORTH BJ, GROVE A, JACKSON CM. Asthma control with salmeterol. Lancet 1994; 344: 760.

C13 LIPWORTH BJ, GROVE A. Bioavailability of salbutamol. Thorax 1994; 49: 1183.

C14 LIPWORTH BJ. Salmeterol in smokers with COPD. Thorax 1996; 51: 110.

C15 LIPWORTH BJ, CLARK DJ. Lung bioavailability of generic versus innovator salbutamol MDI's. Thorax 1996; 51: 658.

C16 LIPWORTH BJ, CLARK DJ. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. British Journal of Clinical Pharmacology 1996; 42: 257-258.

C17 LIPWORTH BJ, CLARK DG. High dose inhaled steroids in asthmatic children. Lancet 1996;348:820

C18 LIPWORTH BJ. 2-adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax 1997; 52: 305.

C19 LIPWORTH BJ. Pharmacokinetics of inhaled drugs. British Journal of Clinical Pharmacology 1997; 44: 213.

C20 LIPWORTH BJ, KEILY DJ. Use of pulsed-wave Doppler echocardiography to measure changes in mean pulmonary arterial pressure - is further validation required? Chest 1997; 111: 1470.

C21 TAN KS, HALL I, LIPWORTH BJ. Dose use or withdrawal of long-acting 2-adrenoceptor agonist induce desensitisation. Lancet 1998; 351: 67.

C22 LIPWORTH BJ. Adrenocortical activity in children. Thorax 1998; 53: 77.

C23 LIPWORTH BJ, JACKSON CM. Fenoterol and asthma morality. Lancet 1998; 352: 486-487.

C24 AZIZ I, LIPWORTH BJ. Exercise induced asthma. New England Journal of Medicine 1998; 339: 1783.

C25 LIPWORTH BJ, WILSON AM. Systemic effects of intranasal corticosteroids. Journal of Allergy and Clinical Immunology 1999; 103: 177-178.

C26 LIPWORTH BJ. Safety of intranasal steroids. Journal of Allergy and Clinical Immunology 1999; 103: 353-354.

C27 LIPWORTH BJ, JACKSON CM. Effect of fluticasone propionate nasal spray on the hypothalamic-pituitary-adrenal axis. Journal of Allergy and Clinical Immunology 1999; 103: 357.

C28 DEMPSEY OJ, WILSON AM, LIPWORTH BJ. Spacer devices increase dose of inhaled corticosteroids delivered. British Medical Journal 1999; 318: 1764.

C29 LIPWORTH BJ, JACKSON CM. Lack of albuterol subsensitivity with salmeterol. American Journal of Respiratory and Critical Care Medicine 1999; 160: 2125-2126.

C30 LIPWORTH BJ, JACKSON CM. Effects of oral and inhaled corticosteroid on the hypothalamic-pituitary-adrenal axis. Journal of Allergy and Clinical Immunology 1999; 104: 713.

C31 LIPWORTH BJ. Use of fluticasone in asthma. Chest 2000; 117: 611-612.

C32 LIPWORTH BJ. Therapeutic ratio of inhaled fluticasone. Thorax 2000; 55: 252-253.

C33 WILSON AM, BLUMSOHN A, JUNG RJT, LIPWORTH BJ. Asthma and Cushing's syndrome. Chest 2000; 117: 593-594.

C34 LIPWORTH BJ, JACKSON CM. Equivalence of hydrofluoroalkane (HFA) and chlorofluorocarbons (CFC) formulations of inhaled beclomethasone. Respiratory Medicine 2000; 94: 177-183.

C35 LIPWORTH BJ, JACKSON CM. Airway hyperresponsiveness with long-term salmeterol therapy. Chest in press.

C36 FOWLER SJ, LIPWORTH BJ. Therapeutic equivalence of inhaled salbutamol. Thorax 2000; 55: 347-348.

C37 LIPWORTH BJ, JACKSON CM. Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. American Journal of Respiratory and Critical Care Medicine 1999; 160: 2125-2126.

C38 LIPWORTH BJ, JACKSON CM. Salmeterol and tolerance. Chest 2000; 117: 609-610.

C39 LIPWORTH BJ, JACKSON CM. Inhaled corticosteroids and bone density. Lancet 2000; 356: 425.

C40 DEMPSEY OJ, LIPWORTH BJ. Intravenous montelukast in acute asthma: expensive aminophylline? Thorax 2000; 55: 808-809.

C41 LIPWORTH BJ. Relative effects of exogenous inhaled corticosteroids on diurnal cortisol secretion. Archives of Internal Medicine 2000; 160: 2549-2550.

C42 LIPWORTH BJ, JACKSON CM. Influences on plasma cortisol of different formulations of beclomethasone dipropionate. British Journal of Clinical Pharmacology 2000; 50: 381.

C43 LIPWORTH BJ, FOWLER SJ, WILSON A. Fluticasone propionate bioavailability in asthma. Lancet 2000; 356: 1681.

C44 LIPWORTH BJ. Study shows dissociation between objective and subjective responses to homeopathy in allergic rhinitis. British Medical Journal 2001; 322: 169.

C45 LIPWORTH BJ. Systemic absorption of inhaled steroids. The Asthma Journal 2001; 6(1): 45-46.

C46 LIPWORTH BJ. Fluticasone and cortisol measurements. Chest 2001; 119: 984.

C47 LIPWORTH BJ. Salmeterol and conventional asthma therapy. Chest 2001; 119: 986.

C48 LIPWORTH BJ. Mometasone furoate levels. Chest 2001, 120: 1034-1035.

C49 LIPWORTH BJ. The problem of dose-response and therapeutic ratio of inhaled steroids. American Journal of Respiratory and Critical Care Medicine 2001; 163: 1758.

C50 LIPWORTH BJ, JACKSON CM. Inhaled triamcinolone and chronic obstructive pulmonary disease. New England Journal of Medicine 2001; 344: 1553.

C51 LIPWORTH BJ. Eosinophils and airway hyper-responsiveness. Lancet 2001; 357: 1446.

C52 LIPWORTH BJ, JACKSON CM. Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide suspension for infants and young children with persistent asthma. Am J Respir Crit Care Med 2001; 163: 1277a-1278.

C53 LIPWORTH BJ. Fluticasone propionate/salmeterol combination. JACI 2001; 107 (Number 4): 476.

C54 LIPWORTH BJ. Dose proportionality of fluticasone proportionate hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med 2000; 94 (Suppl B): S10-S16.

C55 LIPWORTH BJ, WILSON AM. Montelukast and Churg-Strauss syndrome. Thorax Med 2001; 56: 244.

C56 LIPWORTH BJ. Revisiting interactions between hypoxaemia and 2 agonists in asthma. Thorax 2001; 56: 506-507.

C57 LIPWORTH BJ. Lost in the Labyrinth on endpoints. Chest 2001; 120: 323-324.

C58 LIPWORTH BJ, CURRIE G, FOWLER S. On-demand relief treatment for asthma. Lancet 2001; 357; 1882.

C59 LIPWORTH BJ, FOWLER S. Association between atopic status and airway reactivity to methacholine and adenosine monophosphate. European Respiratory Journal 2001; 18 (Suppl 33): 1025.

C60 LIPWORTH BJ, FOWLER S, CURRIE, G. Montelukast for persistent asthma. Lancet 2001; 358, 1455.

C61 LIPWORTH BJ. Systemic effects of inhaled steroids. Thorax 2001; 56: 980-983.

C62 LIPWORTH BJ. Systemic bioavailability of fluticasone propionate. British Journal of Clinical Pharmacology 2001; 52: 455-460.

C63 FOWLER SJ, LIPWORTH BJ. Addition of salmeterol to ICs may improve overall asthma control. JAMA 2001; 286 No 24: 3076-3077.

C64 LIPWORTH BJ. Duration of steroid therapy determines dose-response effect. Chest 2002; 121: 306.

C65 LIPWORTH BJ, CURRIE GP. Effects of leukotriene receptor antagonists on bronchial hyperresponsiveness: a meta-analysis. JACI 2002; 109 (Part 2): S241.

C66 LIPWORTH BJ. Budesonide dose-response in mild persistent asthma. Am J Respir Crit Care Med 2002; 165: 1188-1189.

C67 LIPWORTH BJ, JACKSON CM. Bronchodilator reversibility to albuterol predicts bronchodilator response to salmeterol. Chest 2002; 121: 1382.

C68 LIPWORTH BJ, CALHOUN WJ. The step 3 dilemma for moderate persistent asthma. Am J Respir Crit Care Med 2002; 165: 1022-1023

C69 LIPWORTH BJ. Effects of the theophylline on airway eosinophils. Am J Respir Crit Care Med 2002; 165: 845.

C70 LEE DKC, CURRIE GP, LIPWORTH BJ. Predictive parameters of dropout during inhaled corticosteroid tapering. Chest 2002; 121: 1726-1727.

C71 CURRIE GP, SYME-GRANT NJ, MCFARLANE LC, CAREY FA, LIPWORTH BJ. Effects of low dose fluticasone/salmeterol on diffeent surrogate inflammatory markers in moderate persistent asthma. Am J Respir Crit Care Med 2002; 165 (Part 2) B46.

C72 CURRIE GP, FOWLER SJ, LIPWORTH BJ. Dose-response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Am J Respir Crit Care Med 2002; 165 (Part 2): B40.

C73 CURRIE G, HAGGART K, LEE D, FOWLER S, WILSON A, BRANNAN J, ANDERSON A, LIPWORTH BJ. Effects of histamine and leukotriene antagonism on mannitol and adenosine monophosphate challenge. Am J Respir Crit Care Med 2002; 165 ( Part 2): B40.

C74 CURRIE G, LEE D, DEMPSEY O, FOWLER S, COWAN L, LIPWORTH BJ. Addivity of montelukast in salmeterol treated moderate persistent asthmatics. Am J Respir Crit Care Med 2002; 165 (Part 2): B44.

C75 SIMS E, LIPWORTH BJ. Sustained bronchoprotection with montelukast but not formtoterol as add on therapy in asthmatics with the homozygous glycine 16b2 adrenoceptor genotype. J Allergy Clin Immunol 2002; 109 (Part 2): S157

C76 LIPWORTH BJ. Which is better for fall in nitric oxide? Annals of Allergy, Asthma & Immunol 2002; 89: 530

C77 LIPWORTH BJ. Conventional RIA underestimates cortisol suppression in the presence of prednisolone. Thorax 2002; 57:837-838

C78 LIPWORTH BJ, LEE DKC, CURRIE GP, GRAY RD. Combined mediator blockade or topical corticosteroids for seasonal allergic rhinitis. J Allergy Clin Immunol 2002;110 (part 1):939

C79 LIPWORTH BJ, JACKSON CM. Marginal benefits of adding formoterol. Thorax 2002; 57: 1089

C80 LIPWORTH BJ. Don't forget to examine the nose. British Medical Journal 2002;

C81 LIPWORTH BJ. Second line controller treatment might have been tried. British Medical Journal 2002; 325: 836

C82 LIPWORTH BJ. Over the precipice with off label prescribing. British Medical Journal 2002;

C83 LIPWORTH BJ, FOWLER SJ, CURRIE GP, WILSON AM, HOLT S. Anti-inflammatory end points. British Medical Journal 2002;

C84 LIPWORTH BJ, LEE DKC, CURRIE GP, GRAY RD. Combined mediator blockade or topical corticosteroids for seasonal allergic rhinitis. J Allergy Clin Immunol 2002;110:939

C85 CURRIE GP, LEE DKC, LIPWORTH BJ. Asthma exacerbations and sputum eosinophil counts. Lancet 2003;361:1302-1303.

C86 LIPWORTH BJ, LEE DKC, JACKSON CM. Decongestant effects of antihistamine: A class effect? J Allergy Clin Immunol 2003;111:653.

C87 JACKSON CM, LIPWORTH BJ. Lung bioavailability of spacers. Ann Allergy Asthma Immunol 2003;90:674

C88 LIPWORTH BJ, JACKSON CM. Effects of salmeterol on smooth muscle versus inflammatory outcomes. J Allergy Clin Immunol 2003;112:223

C89 LIPWORTH BJ, LEE DKC, JACKSON CM. Nebulised salbutamol and magnesium sulphate in acute asthma. Lancet 2003; 362:1079

C90 LIPWORTH BJ, FARDON TC. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2004;113:178

C91 FARDON TC, GRAY RD, LIPWORTH BJ. Asthma exacerbations and inhaled corticosteroids. The Lancet 2004;363:1235

C92 FARDON TC, CURRIE GP, LEE DKC, LIPWORTH BJ. Lower thresholds for bronchial challenge testing. Allergy 2004;59:1125-1126

C93 LEE DKC, LIPWORTH BJ. Intranasal and inhaled corticosteroids in allergic rhinitis and asthma. Br J Clin Pharm 2004;58:447-448

C94 LEE DKC, CURRIE GP, LIPWORTH BJ. Combination therapy with a long-acting beta 2 agonist and an inhaled corticosteroid as initial maintenance treatment in asthma. Annals of Allergy, Asthma and Immunology 2005;94:410-412

C95 LEE DKC, CURRIE GP, LIPWORTH BJ. H1-Antihistamines. N Engl J Med 2005;352:115-116

C96 FARDON TC, LIPWORTH BJ. An own GOAL or a real breakthrough. Am J Respir Crit Care Med 2005;171:1060

C97 LEE DKC, CURRIE GP, LIPWORTH BJ. In vitro synergism of inhaled corticosteroid and long-acting B2-agonist is not translated clinically in vivo. J Allergy Clin Immunol 2005;115:880

C98 LEE DKC, LIPWORTH BJ. Lack of efficacy of petasites hybridus (butterbur) in allergic rhinitis. Focus Alt Complement Ther 2005;10:19-21

C99 LIPWORTH BJ, MENZIES DANIEL. Systemic bioavailability of fluticasone in COPD. Am J Respir Crit Care Med 2005;171:1191

C100 MENZIES D, FARDON T, BURNS P, LIPWORTH BJ. Comparison of measured exhaled nitric oxide at varying flow rates. Thorax 2005;60:788

C101 LIPWORTH BJ, MENZIES D. Systemic versus topical glucocorticoid therapy for acute asthma. AJRCCM 2005;172:1055

C102 BARNES ML, LIPWORTH BJ. Clinical importance of the Step 3 choice in asthma. Thorax 2006;61:180-181

C103 JACKSON CM, LIPWORTH BJ. Beta-2 adrenergic receptor genotype and survival after acute coronary syndrome. JAMA 2006;295:757

C104 CURRIE GP, LEE DKC, LIPWORTH BJ. Evaluating the effects of "triple therapy" with inhaled corticosteroids, long-acting 2 agonists, and leukotriene modifiers in asthma.. Chest 2006;130:301

C105 JACKSON C, LIPWORTH BJ. Salmeterol Response and B2 Adrenergic Receptor Genotype. JACI 2007;120:217-218

C106 MENZIES D, LIPWORTH BJ. Respiratory symptoms and inflammation after a smoking ban. JAMA 2007;297:359-360

C107 LIPWORTH BJ. Benefits of long-acting B2-agonists. JACI 2007;120:725

C108 VAIDYANATHAN S, NAIR A, LIPWORTH B. Comment on: 'Obtaining concomitant control of allergic rhinitis and asthma with intranasal corticosteroid.' Allergy 2007:62;1214

C109 JACKSON CM, LIPWORTH BJ. Benefits of combination therapy on exacerbation in non-smoking patients with asthma. J Allergy Clin Immunol 2008;121:780

C110 VAIDYANATHAN S, WILLIAMSON P, LIPWORTH BJ. Comment on: Nitric oxide evaluation in upper and lower respiratory tracts in nasal polyposis. Clinical and Experimental Allergy 2008:38;1697

C111 CLEARIE K, LIPWORTH BJ. Levalbuterol Kinetics. J Allergy Clin Immunol 2009;123:275

C112 LIPWORTH BJ. Long-Acting beta-2 agonists and inhaled corticosteroids in asthma. Am J Respir Crit Care Med 2009; 179: 853-854

C113 WILLIAMSON PA, CLEARIE K, VAIDYANATHAN S, LIPWORTH B. Effects of methacholine challenge on alveolar nitric oxide. Thorax 2009;64:549-550

C114 WILLIAMSON P, SHORT P, McKINLAY L, PALMER C, LIPWORTH B. B-agonist safety and the elephant in the room? Thorax 2011;66:542

C115 LIPWORTH BJ, MUKHOPADHYAY S, PALMER C. Step-up therapy for children with uncontrolled asthma while receiving inhaled corticosteroids. N Engl J Med 2010;363:90-92

C116 HANANIA N, MANNAVA B, FRANKLIN A, LIPWORTH B, WILLIAMSON P, GARNER W, DICKEY B, BOND R. Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J 2010;36:963-965

C117 WILLIAMSON P, MENZIES D, CLEARIE K, VAIDYANTHATAN S, LIPWORTH B. Dose response for inhaled fluticasone on airway and systemic inflammation in COPD. Eur Respir J 2011;37:206-209

C118 LIPWORTH B, JACKSON C. Comparable in vivo anti-inflammatory potency at trough using inhaled fluticasone furoate and propionate. Allergy 2011;66:699

C119 LIPWORTH BJ, CLEARIE K. Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone and salmeterol: a reply. Br J Clin Pharmacol 2011;72:355-356

C120 LIPWORTH BJ, CLEARIE K. Guidelines to establish relative potency are not in touch with reality. Br J Clin Pharmacol 2011;72:834-835

C121 McKINLAY L, VAIDYANATHAN S, WILLIAMSON P, LIPWORTH BJ. Nasal nitric oxide as a measure of ostiomeatal complex patency in polyp disease. Ann Allergy Asthma Immunol 2011;107:179-180

C122 VAIDYANATHAN S, BARNES M. WILLIAMSON P, HOPKINSON P, DONNAN P, LIPWORTH B. Combined oral and intranasal corticosteroid therapy for nasal polyps. Ann Intern Med 2011;155:277-278

C123 LIPWORTH BJ, JACKSON CM. Leukotriene antagonists in asthma. N Engl J Med 2011;365:272-273

C124 LIPWORTH BJ. Cardiac beta-2 adrenoceptor responses to formoterol and associated corticosteroid interactions. Ann Allergy Asthma Immunol 2012;108:68

C125 LIPWORTH BJ. Commentary - Review: Tiotropium mist inhlaer increase mortality in chronic obstructive pulmonary disease. ACP Journal Club 2011;155:JC4-6

C126 LIPWORTH BJ. Adrenal suppression with fluticasone furoate. Ann Allergy Asthma Immunol 2013;110:213

C127 LIPWORTH BJ, SHORT P. Explaining differential effects of tiotropium on mortality in COPD. Thorax 2013;doi:10.1136/thoraxjnl-2012-203176

C128 LIPWORTH BJ, MANOHARAN A, SHORT P. Tiotropium in Asthma. N Eng J Med 2012;367:2552

C129 LIPWORTH BJ, MANOHARAN A, SHORT P. Adverse effects of long acting beta-agonists on airway hyper-responsiveness. Am J Respir Cell Mol Biol 2013, In Press

C130 LIPWORTH BJ. Safety of fluticasone furoate/vilanterol combination. Thorax 2013, doi:10.1136/thoraxjnl-2013-203910

C131 LIPWORTH BJ. Assessment of the small airways asthma phenotype. Ann Allergy Asthma Immunol 2013. In press BACK TO TOP



University Logo Asthma Allergy Research Banner